- Home
- BGI vs HOOK Comparison
BGI vs HOOK Comparison
Compare BGI & HOOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGI
- HOOK
- Stock Information
- Founded
- BGI 1879
- HOOK 2011
- Country
- BGI Canada
- HOOK United States
- Employees
- BGI N/A
- HOOK N/A
- Industry
- BGI
- HOOK Biotechnology: Pharmaceutical Preparations
- Sector
- BGI
- HOOK Health Care
- Exchange
- BGI Nasdaq
- HOOK Nasdaq
- Market Cap
- BGI 17.8M
- HOOK 15.3M
- IPO Year
- BGI 2005
- HOOK 2019
- Fundamental
- Price
- BGI $0.86
- HOOK $1.14
- Analyst Decision
- BGI
- HOOK Buy
- Analyst Count
- BGI 0
- HOOK 4
- Target Price
- BGI N/A
- HOOK $10.67
- AVG Volume (30 Days)
- BGI 98.5K
- HOOK 54.0K
- Earning Date
- BGI 07-29-2025
- HOOK 08-07-2025
- Dividend Yield
- BGI N/A
- HOOK N/A
- EPS Growth
- BGI N/A
- HOOK N/A
- EPS
- BGI N/A
- HOOK N/A
- Revenue
- BGI $131,596,265.00
- HOOK $9,351,000.00
- Revenue This Year
- BGI N/A
- HOOK N/A
- Revenue Next Year
- BGI N/A
- HOOK N/A
- P/E Ratio
- BGI N/A
- HOOK N/A
- Revenue Growth
- BGI 4.01
- HOOK N/A
- 52 Week Low
- BGI $0.76
- HOOK $0.72
- 52 Week High
- BGI $2.95
- HOOK $6.68
- Technical
- Relative Strength Index (RSI)
- BGI 44.88
- HOOK 33.34
- Support Level
- BGI $0.77
- HOOK $1.13
- Resistance Level
- BGI $0.98
- HOOK $1.25
- Average True Range (ATR)
- BGI 0.06
- HOOK 0.06
- MACD
- BGI -0.01
- HOOK -0.00
- Stochastic Oscillator
- BGI 47.43
- HOOK 4.55
About BGI Birks Group Inc.
Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.